摘要
目的探讨阿托伐他汀对血液透析治疗患者心功能及血清可溶性ST2与半乳糖凝集素3(Galectin-3)水平的影响,为透析相关治疗提供参考。方法前瞻性选取2017年3月至2020年3月合肥市滨湖医院肾内科血液透析中心的维持性血液透析患者60例,采用随机数字表分成治疗组(n=30)与对照组(n=30)。对照组患者在血液透析治疗中常规注射重组人促红细胞生成素并控制血压等,治疗组患者则在透析治疗同时予以口服阿托伐他汀(10~20 mg/d)治疗。2组均连续治疗3个月,治疗期均严密监测患者体征变化等。比较2组患者治疗前、治疗3个月后心功能指标[左室射血分数(LVEF)、心排血量(CO)以及室间隔舒张末期厚度(LVST)]、血清可溶性ST2、Galectin G3水平及不良反应发生情况。结果治疗3个月后,治疗组患者的LVEF、CO水平[(5.00±0.64)L/min、(67.34±7.71)%]较治疗前[(4.10±0.42)L/min、(55.13±7.61)%]显著升高,且治疗组显著高于对照组[(4.20±0.24)L/min、(57.61±7.28)%],差异均有统计学意义(P<0.05);治疗前、治疗3个月后,2组LVST水平比较均无明显变化,差异无统计学意义(P>0.05)。治疗3个月后,治疗组患者的血清可溶性ST2、Galectin-3水平[(12.74±7.36)、(6.34±4.20)ng/mL]均较治疗前[(22.09±8.83)、(12.62±6.54)ng/mL]显著下降,且治疗组显著低于对照组[(24.21±9.24)、(14.51±6.47)ng/mL],差异均有统计学意义(P<0.05)。2组患者治疗中均无严重的用药不良反应发生,安全性高。结论在血液透析治疗过程中,阿托伐他汀的应用能够有效降低血清可溶性ST2、Galectin-3水平,显著改善患者的心功能且用药安全性较高,具有一定的应用价值。
Objective To investigate the influence of atorvastatin on heart function and serum soluble ST2 and galectin-3 serum levels in patients treated with hemodialysis(MICE),and to provide references for dialyzation-related treatment.Methods From March 2017 to March 2020,60 patients with maintenance hemodialysis in the Nephrology Hemodialysis Center of Hefei Binhu Hospital were prospectively selected and divided into treatment group(n=30)and control group(n=30)by random numbers.Patients in the control group were given regular injections of recombinant human erythropoietin and blood pressure during hemodialysis treatment,while patients in the treatment group were given oral atorvastatin(10~20 mg/d)during dialysis treatment.Both groups were treated continuously for 3 months,and signs of patients were closely monitored during the treatment period.Cardiac function indicators(left ventricular ejection fraction(LVEF),cardiac output volume(CO)and ventricular septal end diastolic thickness(LVST)),serum soluble ST2 and Galectin G3 levels and adverse reactions were compared between the two groups before and after treatment.Results After 3 months of treatment,the levels of LVEF and CO in the treatment group patients[(5.00±0.64)L/min,(67.34±7.71)%]were significantly higher than those before treatment[(4.10±0.42)L/min,(55.13±7.61)%],and the levels of LVEF and CO in the treatment group were significantly higher than those in the control group[(4.20±0.24)L/min,(57.61±7.28)%],the differences were statistically significant(P<0.05).Before treatment,after 3 months of treatment,there was no significant change in LVST levels in the two groups,and the differences were not statistically significant(P>0.05).The levels of serum soluble ST2 and Galectin-3 in the treatment group patients[(12.74±7.36),(6.34±4.20)ng/mL]were significantly lower than before treatment[(22.09±8.83),(12.62±6.54)ng/mL],and levels of serum soluble ST2 and Galectin-3 in the treatment group were significantly lower than those in the control group[(24.21±9.24),(14.51±6.47)ng/mL],the differences were statistically significant(P<0.05).No serious adverse drug reactions occurred in the treatment of the two groups,and the safety was high.Conclusion In the process of hemodialysis,atorvastatin can effectively reduce the serum soluble ST2 and Galectin-3 levels,significantly improve the cardiac function of patients with high drug safety,and can provide a certain reference for clinical dialysis treatment,with certain application value and significance.
作者
董婧
肖蓓
林辉
DONG Jing;XIAO Bei;LIN Hui(Department of Nephrology,The Third Affiliated Hospital of Anhui Medical University(Hefei Binhu Hospital),Hefei Anhui 230000,China)
出处
《临床和实验医学杂志》
2021年第8期842-845,共4页
Journal of Clinical and Experimental Medicine
基金
安徽省高校自然科学研究重点项目(编号:KJ2016A401)。
